Methyl 2-(2-tert-butoxycarbonylamino-3-phenyl-propionylamino)-3-phenylpropanoate | 15215-74-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl 2-(2-tert-butoxycarbonylamino-3-phenyl-propionylamino)-3-phenylpropanoate
• 英文别名: methyl 2-(2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-3-phenylpropanoate；Boc-Phe-Phe-OMe；Methyl 2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]-3-phenylpropanoate
• CAS: 15215-74-4；94202-58-1
• 化学式: C₂₄H₃₀N₂O₅
• 分子量: 426.513
• InChiKey: QRVYORSLWSKRKN-UHFFFAOYSA-N

物化性质

• 熔点：
  108-110 °C
• 沸点：
  621.0±55.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  93.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY
  申请人：University of Kentucky Research Foundation

  公开号：US20190083519A1

  公开（公告）日：2019-03-21

  Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.

  米司麦霉素侧链羧酸（MTM-SA）衍生物包括一种取代氨基酸衍生物、一种取代氨基酸二肽衍生物或一种未取代的二肽衍生物。这些MTM-SA衍生物对于治疗与异常红细胞转化特异性转录因子相关的癌症或神经疾病很有用。独特的MTM-SA衍生物对ETS转录因子具有增强的选择性。
• CHIRAL FLUORINATING REAGENTS
  申请人：ISIS INNOVATION LIMITED

  公开号：US20150284401A1

  公开（公告）日：2015-10-08

  This invention relates to fluorinating agents and, more particularly, to chiral non-racemic fluorinating agents useful for enantioselective fluorination, as well as to their synthesis and use and other subject matter. The fluorinating agents are based on a substituted 1,4-diazabicyclo[2.2.2]octane (DABCO) skeleton and provide electrophillic fluorine enantioselectively.

  本发明涉及氟化剂，更具体地涉及手性非外消旋氟化剂，可用于对映选择性氟化，以及它们的合成、使用和其他相关主题。该氟化剂基于取代的1,4-二氮杂双环[2.2.2]辛烷（DABCO）骨架，并提供电子亲和性氟的对映选择性。
• Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US10550150B2

  公开（公告）日：2020-02-04

  The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (κ) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said short-chain peptides, and pharmaceutical compositions containing them and their use.

  本发明涉及通式(I)的新型短链肽，它们是选择性和外周作用的KOR激动剂、它们的同分异构体、它们的对映体、它们的非对映异构体、它们的立体异构体、它们的药学上可接受的盐、或其原药，可用于治疗或预防涉及卡巴（κ）阿片受体（KOR）的疾病，如治疗或预防内脏痛、痛觉减退、风湿性关节炎炎症、骨关节炎炎症、肠道疾病炎症、肠易激综合征炎症、眼部炎症、耳部炎症或自身免疫性炎症。本发明还涉及上述短链肽的制造工艺、含有短链肽的药物组合物及其用途。
• Mithramycin derivatives having increased selectivity and anti-cancer activity
  申请人：University of Kentucky Research Foundation

  公开号：US11224609B2

  公开（公告）日：2022-01-18

  Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.

  提供了米曲霉素侧链羧酸（MTM-SA）衍生物，其中包括取代的氨基酸衍生物、取代的氨基酸二肽衍生物或未取代的二肽衍生物。MTM-SA 衍生物可用于治疗与红细胞转化特异性转录因子异常有关的癌症或神经疾病。独特的 MTM-SA 衍生物对 ETS 转录因子的选择性增加。
• NOVEL SHORT-CHAIN PEPTIDES AS KAPPA OPIOID RECEPTORS (KOR) AGONIST
  申请人：Cadila Healthcare Limited

  公开号：EP3294315A2

  公开（公告）日：2018-03-21

表征谱图